Skip to main content Skip to Footer


March 13, 2014
Managing R&D pipeline risks a top priority for life sciences (5 of 6)
By: Anne O'Riordan

In general, life sciences companies are more confident in their capabilities to deal with R&D pipeline risks than supply chain and joint partner risks, according to Accenture’s 2013 Global Risk Management Study.

Nearly 60 percent of surveyed companies use a comprehensive set of risk categories in managing R&D pipeline risks, and more than half use risk analytics to address R&D-related risks. Even better news is that each approach we surveyed is employed by at least 40 percent of respondents.

Sophisticated Means of Addressing Risks Related to R&D

Join me next week when I conclude my series by looking at how organizations are responding to the hot topic of regulatory change and healthcare reform.

To learn more:

More blogs on this topic